c5252
Biologicalexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05095441)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07243340 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2025 | ImmVira Pharma Co. Ltd |
| NCT06126744 | Phase 1 | Feb 1, 2024 | Duke University |
| NCT05095441 | Phase 1 | Dec 31, 2021 | ImmVira Pharma Co. Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmVira Pharma Co. Ltd | For profit | 2 | 2 | 2 | 2021 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1